CatCHimera Liver Cancer Recurrence Detection Platform

Exhibitor: TCM BIOTECH INTERNATIONAL CORP.

Booth No: L330

Characteristic

The liver cancer detection platform utilizes exclusive patent technology in liver cancer liquid biopsy. It detects hepatitis B virus-specific fusion DNA as a biomarker to precisely monitor and differentiate patients at high risk of recurrence. Detection of fusion DNA post-surgery indicates residual tumors, raising the risk of recurrence by 14 times.

This novel technology, licensed in 2015 from the National Taiwan University College of Medicine, reflects years of research collaboration with NTU's team in developing precision medical testing products. It combines next-generation sequencing (NGS) and droplet digital PCR (ddPCR), offering higher specificity and sensitivity than NGS alone, reducing background signal interference and targeting mutation sites more accurately. It's the world's first post-surgical recurrence tracking test for hepatitis B-related liver cancer.

Clinical validation studies at four medical centers involving 116 cases showed that regular blood monitoring within 14 months post-surgery detected residual tumors 3 to 9 months earlier compared to current CT imaging-based post-surgical tracking. When combined with existing health insurance-covered tests like AFP and PIVKA-II, sensitivity can reach up to 95.7% and specificity up to 96.7%. In contrast, AFP alone has a sensitivity of only 43.5%, highlighting the platform's potential to fill gaps in current hepatitis B-related liver cancer recurrence detection.